Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212
J. Clin. Invest. J. Ludovic Croxford, et al. 111:1231 doi:10.1172/JCI17652 [
Go to this article.]
Figure 4Cannabinoid treatment inhibits both virus and myelin autoimmune inflammatory DTH responses. Treatment of mice with R(+)WIN55,212 (black bars) at the time of TMEV infection (
a), at the onset of clinical disease (
b), or during established disease (
c), significantly reduces DTH responses to rechallenge with either the immunodominant TMEV peptide VP2
70-86 or the autoreactive myelin PLP
139-151 peptide. *Significant reduced DTH responses compared with either S(–)WIN55,212 (dark gray bars) or untreated TMEV-infected (white bars) mice (
P < 0.05). Naive mice (light gray bars) show a low background response to either peptide.
